Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11316867

DNA microarray analysis of complex biologic processes.

Manjula Kurella·Li-Li Hsiao·Takumi Yoshida·Jeffrey D Randall·Gary Chow·Satinder S Sarang·Roderick V Jensen·Steven R Gullans
View original source ↗Export metadata ↓

Abstract

DNA microarrays, or gene chips, allow surveys of gene expression, (i.e., mRNA expression) in a highly parallel and comprehensive manner. The pattern of gene expression produced, known as the expression profile, depicts the subset of gene transcripts expressed in a cell or tissue. At its most fundamental level, the expression profile can address qualitatively which genes are expressed in disease states. However, with the aid of bioinformatics tools such as cluster analysis, self-organizing maps, and principle component analysis, more sophisticated questions can be answered. Microarrays can be used to characterize the functions of novel genes, identify genes in a biologic pathway, analyze genetic variation, and identify therapeutic drug targets. Moreover, the expression profile can be used as a tissue or disease "fingerprint." This review details the fabrication of arrays, data management tools, and applications of microarrays to the field of renal research and the future of clinical practice.

Explore related subjects

Drug DesignGene Expression ProfilingHumansKidney DiseasesOligonucleotide Array Sequence AnalysisPhenotypeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Manjula Kurella, Li-Li Hsiao, Takumi Yoshida, Jeffrey D Randall, Gary Chow, Satinder S Sarang, Roderick V Jensen, Steven R Gullans. 2001. DNA microarray analysis of complex biologic processes.. https://doi.org/10.1681/asn.v1251072

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

One-dimensional molecular representations and similarity calculations: methodology and validation.

Drug discovery research is increasingly dedicated to biological screening on a massive scale, which seems to imply a basic rejection of many computer-assisted techniques originally designed to add rationality to the early stages of discovery. While ever-faster and more clever 3D methodologies continue to be developed and rejected as alternatives to indiscriminant screening, simpler tools based on 2D structure have carved a stable niche in the high-throughput paradigm of drug discovery. Their staying power is due in no small part to simplicity, ease of use, and demonstrated ability to explain structure-activity data. This observation led us to wonder whether an even simpler view of structure might offer an advantage over existing 2D and 3D methods. Accordingly, we introduce 1D representations of chemical structure, which are generated by collapsing a 3D molecular model or a 2D chemical graph onto a single coordinate of atomic positions. Atoms along this coordinate are differentiated according to elemental type, hybridization, and connectivity. By aligning 1D representations to match up identical atom types, a measure of overall structural similarity is afforded. In extensive structure-activity validation tests, 1D similarities consistently outperform both Daylight 2D fingerprints and Cerius(2) pharmacophore fingerprints, suggesting that this new, simple means of representing and comparing structures may offer a significant advantage over existing tried-and-true methods.

Drug Design↗